Skip to main content
. 2018 Apr 17;21(12):2151–2157. doi: 10.1111/1756-185X.13306

Table 1.

Origin‐specific distribution of ABD symptoms and signs in Innsbruck compared to other cohorts

Signs/symptoms ICBD dataset (p1) German cohort (p2) Turkish cohort (p3) Innsbruck cohort
Total Austrian origin (p4) Turkish origin
Oral aphthae 98%* 99% 100% 93% 94% 94%
Genital aphthae 74%* 65%# 80%* 62% 56% 53%
Skin manifestations 70%** 73%# 93%** 47% 56%# 24%
Ocular manifestations 55%# 43% 35% 46% 56% 47%
Musculoskeletal manifestations 51%* 52% 74% 65% 67% 59%
Neurological manifestations 17% 20% 4%* 21% 22% 24%
Vascular manifestations 19%* 21% 12%* 30% 22% 29%
Urological manifestations 7% 15% 0%n.d. 7% 6% 12%
Gastrointestinal manifestations 6%** 17% 0%** 21% 11%# 41%
Cardiological manifestations 2% 3% 0%n.d. 3% 0% 6%
Lung manifestations 2%** 6% , # 0%n.d. 11% 11% 18%
Renal manifestations 0%n.d. 2% 0%n.d. 1% 0% 6%
Positive pathergy test 47% 31% n.d. 40% 33% 67%
Family history positive for ABD 11%* 4% n.d. 26% 14% 38%
HLA‐B51 positivity 51% 43% n.d. 56% 47%# 11%

Data are given for the Innsbruck cohort (with subgroups of defined Austrian and Turkish background, = 18 and = 17, respectively) compared to international patients recruited for the International Criteria for Behçet's Disease (ICBD) dataset,14 from the German cohort (= 7125) and a Turkish cohort (= 10713). P‐values are calculated using Fisher's exact test of significance (#< 0.1; *< 0.05; **< 0.01) for comparison between the ICBD dataset with data of the total Innsbruck cohort (p1), between the Austrian patients of the Innsbruck cohort and those of the German cohort (p2), and between the Turkish patients of the Innsbruck cohort and those of the Turkish cohort (p3). †Data from patients with German origin (representing 39% of the German cohort, including those with significant differences to the total German cohort). ABD, Adamantiades–Behçet's disease; HLA, human leukocyte antigen; n.d., not described.